Ayurvedic clinical study for the management of Psoriasis
- Conditions
- Health Condition 1: null- Psoriasis
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
1.Known cases of psoriasis, without psoriatic arthropathy,
Exhibiting psoriatic triad â??
I.Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion
II.Under the scales there appears a pinkish moist tender skin
III.With the scarping of the moist skin there appear tiny blood droplets (Auspitzâ??s sign)
2.Patients suffering from mild to moderate psoriasis with less than 50 % of the body surface involvement
3.Patients having less than 10 years duration
4.Positive histopathological finding.(Skin-biopsy - optional)
1.Age below 18 years and above 60 years
2.Patients with other forms of Psoriasis like Guttate/ Pustular/ Erythrodermic/ inverse.
3.Patients suffering from severe psoriasis with more than 50% of the body surface involvement
4.Patients having chronic disease i.e. more than10 years duration
5.Patients who cannot report in person every 2 weeks in the OPD
6.Patients with Psoriatic arthropathy
7.Patients with poorly controlled Hypertension ( >160/100 mmHg)
8.Patients with poorly controlled Diabetes Mellitus having Hb A1C of > 7.5%
9.Patients on medication with corticosteroids, phototherapy, biologics, antidepressants any other drugs that may have an influence on the outcome of the study.
10.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
11.Symptomatic patient with clinical evidence of Heart failure.
12.Known HIV positive cases
13.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study.
14.Alcoholics and/or drug abusers
15.H/o hypersensitivity to any of the trial drugs or their ingredients
16. Pregnant/lactating woman.
17.Patients who have completed participation in any other clinical trial during the past six months.
18.Any other condition which the Investigator thinks may jeopardize the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â?¢Relief in Signs & Symptoms (Change in baseline in plaque psoriasis) of the disease by Reduction in Psoriasis Area and Severity Index (PASI) Score, PASI 50 (50% improvement in PASI score)Timepoint: 12 Weeks
- Secondary Outcome Measures
Name Time Method â?¢Relief in Signs & Symptoms (Change in baseline in plaque psoriasis) of PASI 25. <br/ ><br>â?¢Improvement in Dermatology Life Quality Index (DLQI) Questionnaire. <br/ ><br>â?¢Any adverse drug reaction or event noted during the trialTimepoint: 12 Weeks